AbbVie plans to build a $1.4 billion, 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The project will integrate advanced manufacturing and laboratory technologies with artificial intelligence to support the production of immunology, neuroscience and oncology medicines.
The company expects construction to begin this year, with completion scheduled for the end of 2028. The first phase of construction will include small volume parenteral (SVP) drug product manufacturing facilities, laboratories, a warehouse, administrative offices and employee wellness facilities.
When completed, the campus will serve as AbbVie's U.S. center of excellence for SVP manufacturing and deliver next-generation medicines to patients worldwide.
Over the next four years, AbbVie plans to hire 734 people, including engineers, scientists, manufacturing operators and laboratory technicians, at the campus. It will also generate more than 2,000 construction jobs during development.
This project is part of the company's $100 billion U.S. commitment over the next decade and builds on manufacturing investments announced in Illinois, Arizona and Massachusetts over the past year.
Headquartered in Illinois, AbbVie employs approximately 29,000 people in the U.S., including more than 6,000 at its U.S. manufacturing campuses.
